Over the past several years, the word robust has proliferated across dermatology literature, podium presentations, clinical trial discussions, pharmaceutical investor decks, and promotional materials. It is used to describe trial designs, efficacy outcomes, safety profiles, experimental methods, and research findings. The problem is not that robust is always wrong. Rather, it is increasingly used as a vague substitute for more precise scientific language. When undefined, robust may leave readers less informed, rather than more, about the strength, reliability, magnitude, durability, or clinical relevance of the evidence.
Merriam-Webster defines robust as “having or exhibiting strength or vigorous health,” “having or showing vigor, strength, or firmness,” and “capable of performing without failure under a wide range of conditions.”1 These ordinary meanings are useful in everyday language, but they become imprecise when applied broadly to clinical trials, efficacy outcomes, safety profiles, or scientific methods. A study can be large but not rigorous, statistically significant but not clinically meaningful, durable but not generalizable, or well tolerated but not definitively safe. Calling any of these findings robust may sound reassuring, but it does not tell the reader which specific attribute is being described.
Key Takeaways
Robust lacks scientific precision. The word carries no quantifiable meaning in clinical or research contexts — no statistical threshold, clinical benchmark, or methodological standard — making it an unreliable descriptor for trial results, safety data, or study design.
Vague language can obscure important nuance. Blanket use of robust may make borderline, heterogeneous, or context-dependent findings appear stronger than the underlying data support, creating a false sense of confidence for clinicians and readers.
Study design deserves specific descriptors. Terms such as well-powered, pragmatic, reproducible, and rigorous each communicate distinct methodological attributes, unlike robust, which conveys none of them.
Efficacy outcomes require directional, magnitude-based language. Phrases such as statistically significant, durable, consistent across subgroups, and clinically meaningful give readers interpretable information about what changed, in which direction, and to what degree.
Safety profiles need precise characterization. Rather than describing a robust safety profile, clinicians and authors should specify tolerability, rate of serious adverse events, treatment discontinuation rates, and whether safety findings are consistent across studied subgroups or extensively characterized across large populations.
Real-world evidence requires fit-for-purpose language. Descriptors such as generalizable, reliable, complete, and representative each answer a distinct question about data quality, and should replace robust when characterizing real-world data sets.
Robust warrants skepticism when used as marketing filler. In pharmaceutical investor decks and promotional materials, the term may create a favorable impression without providing clinicians with interpretable or actionable information, warranting skepticism when encountered in those contexts.
The solution is straightforward: let the data dictate the language. If an effect is large, say large. If it is durable, say durable. Replacing robust with precise, data-driven descriptors improves the clarity of dermatology scholarship, strengthens clinical education, and better serves readers making patient care decisions.
In clinical medicine and science, robust often fails because it lacks quantifiable meaning. It provides no objective scale, statistical threshold, clinical benchmark, or methodological standard. It may also obscure important nuance, making borderline, heterogeneous, or context-dependent findings sound stronger than they are. In some settings, it functions as marketing filler, creating a favorable impression without providing the reader with interpretable information. Most importantly, it can create a false sense of confidence by implying certainty where uncertainty remains.
This is not to say that robust has no legitimate technical use. In statistics and methodology, the term may have a defined meaning, such as robust standard errors, robust regression, robustness checks, or analytic approaches that are less sensitive to model assumptions. The concern is its casual, blanket use to validate study quality, efficacy, safety, or scientific importance.
There are better ways to describe study design and methodology. Although rigorous can also be generic if left unexplained, it at least conveys adherence to high scientific or clinical standards. Well-powered indicates that the study was designed with an adequate sample size to detect a prespecified effect. Pragmatic communicates that the methods reflect real-world clinical practice rather than idealized conditions. Reproducible indicates that consistent results were obtained when experiments were repeated, ideally through independent replication performed on different days or in different settings.
Similarly, clinical and scientific outcomes deserve more specific language. Statistically significant means that an observed finding met a defined statistical threshold and was unlikely to have occurred by chance under the assumptions of the analysis. Durable indicates that a therapeutic or experimental effect persisted over time. Consistent means that similar findings were observed across subgroups, sensitivity analyses, experiments, or study populations. Clinically meaningful indicates that patients experienced a measurable benefit, but this term should be used only when the threshold for clinical meaningfulness is clearly defined.
Real-world evidence and drug attributes also require precision. Rather than describing real-world data as robust, authors can ask whether the data are generalizable, reliable, complete, representative, or fit for purpose. Generalizable suggests applicability to broader, diverse, and less selected patient populations. Reliable indicates that the data were accurately and consistently captured. Complete indicates that key variables, outcomes, and follow-up information were sufficiently available. Fit for purpose indicates that the data source is appropriate for answering the specific research question. Heterogeneous and homogeneous can describe the degree of variation in patient demographics, disease characteristics, comorbidities, treatment histories, or clinical settings.
The same principle applies to safety. Phrases such as “the drug demonstrated a robust safety profile” should be avoided. A more informative statement would be, “The drug was generally well tolerated, with a low incidence of serious adverse events and few treatment discontinuations due to adverse events.” Other useful descriptors include favorable, when benefits clearly outweigh risks; reassuring, when longer-term data or data from higher-risk populations show low rates of adverse events of interest; consistent, when safety findings are similar across studied subgroups; and extensively characterized, when safety has been evaluated across large populations and meaningful durations of exposure.
Ultimately, the goal of scientific writing is to choose the term that directly reflects the specific data point. Words that state directionality and magnitude are often far superior to a blanket descriptor. Increased, decreased, higher, lower, unchanged, greater magnitude, larger effect, smaller effect, sustained response, and reduced incidence all convey information that robust does not. They help the reader understand what changed, in what direction, and to what degree.
Robust is not the first questionable word to proliferate in medical writing. I distinctly remember listening during rounds as a medical student at Vanderbilt University School of Medicine when a distinguished educator argued against the use of endorse in the History of Present Illness section of a medical chart. His point was logical and memorable: Endorse means to agree with, support, or vouch for something, yet patients do not truly endorse their symptoms. They report them. A patient with severe pruritus does not endorse itchy skin; the patient wants relief from itchy skin. Why not simply write, “The patient reported itchy skin,” rather than “The patient endorsed itchy skin”?
Removing the term endorse from medical vernacular may be a daunting task. Eliminating the vague use of robust in dermatology scholarship should be more achievable. The solution is simple: Choose the word that reflects the actual data. If the effect is large, say large. If it is durable, say durable. If it is statistically significant, clinically meaningful, consistent across subgroups, or generalizable to real-world populations, say so directly and define the basis for the claim. Dermatology does not need fewer adjectives; it needs better ones. By replacing robust with precise, data-driven language, we can improve the clarity of our scholarship, the quality of our education, and the confidence of our readers.
Christopher G. Bunick, MD, PhD, is editor in chief of Dermatology Times and an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut.
Reference
- Robust definition. Merriam-Webster. Accessed May 18, 2026. https://www.merriam-webster.com/dictionary/robust
